CY1118618T1 - Παραγωγα πυραζολιου και χρηση τους ως αγωνιστες toy lpar5 - Google Patents

Παραγωγα πυραζολιου και χρηση τους ως αγωνιστες toy lpar5

Info

Publication number
CY1118618T1
CY1118618T1 CY20171100175T CY171100175T CY1118618T1 CY 1118618 T1 CY1118618 T1 CY 1118618T1 CY 20171100175 T CY20171100175 T CY 20171100175T CY 171100175 T CY171100175 T CY 171100175T CY 1118618 T1 CY1118618 T1 CY 1118618T1
Authority
CY
Cyprus
Prior art keywords
lpar5
compounds
formula
receptor
lpa receptor
Prior art date
Application number
CY20171100175T
Other languages
English (en)
Inventor
Marc Nazaré
Detlef Kozian
Andreas Evers
Werngard Czechtizky
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of CY1118618T1 publication Critical patent/CY1118618T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ενώσεις του τύπου (I), όπου τα κατάλοιπα R1 έως R5, V, G και Μ έχουν τις σημασίες που υποδεικνύονται στις αξιώσεις. Οι ενώσεις του τύπου (I) είναι πολύτιμες φαρμακολογικά δραστικές ενώσεις για χρήση στην θεραπεία ποικίλων διαταραχών, για παράδειγμα καρδιαγγειακών διαταραχών όπως θρομβοεμβολικών νοσημάτων ή επαναστένωσης. Οι ενώσεις της εφεύρεσης είναι αποτελεσματικοί ανταγωνιστές του υποδοχέα LPA αιμοπεταλίων LPAR5 (GPR92) και μπορούν γενικά να χρησιμοποιηθούν σε συνθήκες στις οποίες μια ανεπιθύμητη ενεργοποίηση του υποδοχέα LPA αιμοπεταλίων LPAR5, του υποδοχέα LPA μαστοκυττάρων LPAR5 ή του υποδοχέα LPA κυττάρων μικρογλοίας LPAR5 είναι παρούσα ή για τη θεραπεία ή πρόληψη των οποίων προορίζεται μια αναστολή του υποδοχέα LPA των αιμοπεταλίων, μαστοκυττάρων ή κυττάρων μικρογλοίας LPAR5 . Η εφεύρεση περαιτέρω αναφέρεται σε διαδικασίες για την παρασκευή των ενώσεων του τύπου (I), στη χρήση τους, ιδιαίτερα ως δραστικά συστατικά σε φάρμακα, και φαρμακευτικές συνθέσεις που τις περιέχουν.
CY20171100175T 2012-05-18 2017-02-08 Παραγωγα πυραζολιου και χρηση τους ως αγωνιστες toy lpar5 CY1118618T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305552 2012-05-18
EP13723151.0A EP2882715B1 (en) 2012-05-18 2013-05-16 Pyrazole derivatives and their use as lpar5 antagonists
PCT/EP2013/060171 WO2013171317A1 (en) 2012-05-18 2013-05-16 Pyrazole derivatives and their use as lpar5 antagonists

Publications (1)

Publication Number Publication Date
CY1118618T1 true CY1118618T1 (el) 2017-07-12

Family

ID=48446368

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100175T CY1118618T1 (el) 2012-05-18 2017-02-08 Παραγωγα πυραζολιου και χρηση τους ως αγωνιστες toy lpar5

Country Status (22)

Country Link
US (1) US9346762B2 (el)
EP (1) EP2882715B1 (el)
JP (1) JP6257596B2 (el)
KR (1) KR20150010973A (el)
CN (1) CN104302625B (el)
AU (1) AU2013261718B2 (el)
BR (1) BR112014028406A2 (el)
CA (1) CA2871542A1 (el)
CY (1) CY1118618T1 (el)
DK (1) DK2882715T3 (el)
ES (1) ES2612205T3 (el)
HR (1) HRP20170098T1 (el)
HU (1) HUE032890T2 (el)
IL (1) IL235221A (el)
LT (1) LT2882715T (el)
MX (1) MX347615B (el)
PL (1) PL2882715T3 (el)
PT (1) PT2882715T (el)
RU (1) RU2645344C2 (el)
SG (1) SG11201407210SA (el)
SI (1) SI2882715T1 (el)
WO (1) WO2013171317A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2850062B1 (en) 2012-05-18 2017-07-19 Sanofi Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
AU2016277126A1 (en) * 2015-06-12 2017-12-14 Vettore, LLC MCT4 inhibitors for treating disease
BR112019011825A2 (pt) * 2016-12-12 2019-10-22 Vettore Llc composto, enantiômero isolado, composição farmacêutica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em uma amostra biológica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em relação ao transportador de monocarboxilato mct1, ou um mutante do mesmo, em um paciente, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 em um sujeito que necessite do mesmo, uso de um composto e método para obter um efeito em um paciente
WO2024092205A1 (en) * 2022-10-27 2024-05-02 The Trustees Of Indiana University Inhibition of ship1 as a therapeutic strategy for the treatment of alzheimer's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230441B (it) 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
JP4505329B2 (ja) 2002-09-04 2010-07-21 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害薬
EA200970746A1 (ru) 2007-02-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Конденсированные циклические соединения в качестве частичных агонистов ppar-гамма
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
US7919518B2 (en) * 2008-03-07 2011-04-05 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40
BRPI0907974A2 (pt) 2008-03-07 2015-08-04 Acraf Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
TW201038553A (en) * 2009-03-19 2010-11-01 Sanofi Aventis Novel indazole derivatives which inhibit HSP90, compositions containing them and use thereof
JP5640086B2 (ja) * 2009-08-03 2014-12-10 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニＡｚｉｅｎｄｅ Ｃｈｉｍｉｃｈｅ Ｒｉｕｎｉｔｅ Ａｎｇｅｌｉｎｉ Ｆｒａｎｃｅｓｃｏ Ａ．Ｃ．Ｒ．Ａ．Ｆ．Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ １−ベンジル−３−ヒドロキシメチル−１ｈ−インダゾール及びその誘導体の製造方法並びに必要なマグネシウム中間体
US8859775B2 (en) * 2010-09-02 2014-10-14 Merck Patent Gmbh Pyrazolopyridinone derivatives as LPA receptor antagonists
EP2850062B1 (en) 2012-05-18 2017-07-19 Sanofi Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation

Also Published As

Publication number Publication date
PT2882715T (pt) 2016-12-30
KR20150010973A (ko) 2015-01-29
EP2882715B1 (en) 2016-11-09
CN104302625B (zh) 2017-04-19
BR112014028406A2 (pt) 2017-06-27
RU2014151360A (ru) 2016-07-10
MX2014014011A (es) 2015-02-12
WO2013171317A1 (en) 2013-11-21
HUE032890T2 (hu) 2017-11-28
JP2015517514A (ja) 2015-06-22
JP6257596B2 (ja) 2018-01-10
US9346762B2 (en) 2016-05-24
LT2882715T (lt) 2017-02-10
PL2882715T3 (pl) 2017-04-28
EP2882715A1 (en) 2015-06-17
CA2871542A1 (en) 2013-11-21
AU2013261718A1 (en) 2014-12-18
HRP20170098T1 (hr) 2017-03-24
AU2013261718B2 (en) 2017-10-19
US20150141477A1 (en) 2015-05-21
SG11201407210SA (en) 2014-12-30
ES2612205T3 (es) 2017-05-12
RU2645344C2 (ru) 2018-02-21
SI2882715T1 (sl) 2017-03-31
IL235221A (en) 2016-06-30
CN104302625A (zh) 2015-01-21
DK2882715T3 (en) 2017-02-13
MX347615B (es) 2017-05-04

Similar Documents

Publication Publication Date Title
CY1118973T1 (el) Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων
CY1120031T1 (el) Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης
CY1120673T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CY1124068T1 (el) Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6
CY1124882T1 (el) Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn
CY1117638T1 (el) Παραγωγα του 2-(1,2,3-τριαζολ-2-υλο)βενζαμιδιου και του 3-(1,2,3-τριαζολ-2-υλο)πικολιναμιδιου ως ανταγωνιστες του υποδοχεα της ορεξινης
CY1119134T1 (el) Υποδοχεις της νεπριλυσινης
CY1119387T1 (el) Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου
CY1118618T1 (el) Παραγωγα πυραζολιου και χρηση τους ως αγωνιστες toy lpar5
CY1118735T1 (el) Παραγωγα βενζιμιδαζολο-προλινης
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
TN2018000043A1 (en) Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
CY1117580T1 (el) Νεα ετεροκυκλικα παραγωγα και η χρηση τους στη θεραπεια νευρολογικων διαταραχων
MD3468974T2 (ro) Noi derivați de piperidinil, procedeu pentru prepararea lor și compoziții farmaceutice care ii conțin
UY36285A (es) Compuestos que inhiben la proteína mcl-1
CO7131357A2 (es) Compuestos de n-ariltriazol como antagonistas de lpar
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
UY30547A1 (es) Derivados n-sustituidos de la 6-piridin-4-il quinazolin-2-amina, sus estereoisomeros y sales farmacéuticamente aceptables, proceso de preparacion, composiciones y aplicaciones.
CO6660514A2 (es) Derivados de ácido 2 quinolinil acético como compuestos antivirales del vih
EA202091530A1 (ru) Диазаиндольные соединения
UY30282A1 (es) Compuestos quimicos
MX2017014035A (es) Formas solidas novedosas.
CY1116168T1 (el) Συγκρυσταλλοι και αλατα αναστολεων toy ccr3
AR090596A1 (es) Formulaciones farmaceuticas que comprenden antagonistas de ccr3
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια